Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.

CONCLUSION: These results suggest that MAPT may be a promising predictive biomarker for survival and play an essential role in bicalutamide resistance in CaP.
PMID: 32430253 [PubMed - as supplied by publisher]

Source: Urologic Oncology - May 15, 2020 Category: Urology & Nephrology Authors: Sekino Y, Han X, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Shiota M, Takeshima Y, Yasui W, Matsubara A Tags: Urol Oncol Source Type: research